Allergan PLC. (AGN) Stock Rating Reaffirmed by Wells Fargo & Company
Allergan PLC. (NYSE:AGN)‘s stock had its “buy” rating reaffirmed by stock analysts at Wells Fargo & Company in a research report issued to clients and investors on Monday.
AGN has been the subject of several other reports. Barclays PLC reaffirmed an “equal weight” rating on shares of Allergan PLC. in a research report on Monday. BidaskClub lowered shares of Allergan PLC. from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. UBS AG restated an “outperform” rating and issued a $275.00 price objective on shares of Allergan PLC. in a research note on Wednesday, August 9th. Mizuho reissued a “buy” rating and issued a $267.00 target price on shares of Allergan PLC. in a research note on Monday, September 25th. Finally, Argus restated a “buy” rating and set a $280.00 price target on shares of Allergan PLC. in a research note on Monday, August 14th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $271.84.
Allergan PLC. (NYSE:AGN) traded up 2.84% on Monday, reaching $210.77. The company’s stock had a trading volume of 1,799,409 shares. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. The firm has a market capitalization of $70.46 billion, a PE ratio of 6.42 and a beta of 1.15. The stock’s 50 day moving average is $229.79 and its 200-day moving average is $236.07.
Allergan PLC. (NYSE:AGN) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same quarter in the previous year, the firm posted $3.35 EPS. The business’s revenue was up 8.8% compared to the same quarter last year. Analysts predict that Allergan PLC. will post $16.22 EPS for the current year.
Allergan PLC. declared that its board has authorized a stock buyback plan on Monday, September 25th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the company to buy up to 2.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/allergan-plc-agn-stock-rating-reaffirmed-by-wells-fargo-company/1603725.html.
Several hedge funds have recently modified their holdings of the company. Hudock Capital Group LLC boosted its stake in Allergan PLC. by 0.4% in the 2nd quarter. Hudock Capital Group LLC now owns 571 shares of the company’s stock worth $138,000 after purchasing an additional 2 shares during the period. GWM Advisors LLC raised its stake in shares of Allergan PLC. by 0.4% in the 1st quarter. GWM Advisors LLC now owns 1,260 shares of the company’s stock valued at $300,000 after purchasing an additional 5 shares during the period. Burns J W & Co. Inc. NY lifted its holdings in shares of Allergan PLC. by 0.7% in the second quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock valued at $220,000 after purchasing an additional 6 shares in the last quarter. Pacific Center for Financial Services lifted its holdings in shares of Allergan PLC. by 1.3% in the second quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock valued at $132,000 after purchasing an additional 7 shares in the last quarter. Finally, Gilder Gagnon Howe & Co. LLC lifted its holdings in shares of Allergan PLC. by 0.5% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,666 shares of the company’s stock valued at $405,000 after purchasing an additional 9 shares in the last quarter. 82.03% of the stock is owned by institutional investors.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.